This is an AI-generated daily briefing on the latest developments in HEOR, HTA, and market access. I've found it genuinely useful and decided to make it public.
Examining HTA methodologies in humanitarian crises, incorporating social determinants, blockchain for RWE security, and post-Brexit access challenges in Northern Ireland.
Spotify AppleExamining the evolving role of patient advocacy in evidence generation, ESG integration into pricing, value demonstration challenges for first-in-class drugs, and HTA development in low-resource settings.
Spotify AppleExamining HCA's profit warning, subcutaneous Leqembi's HEOR challenges, FTC insulin settlement implications, and ICER's scientific advice expansion.
Spotify AppleExamining subcutaneous Leqembi’s access potential, HCA’s uninsured care surge, CVS insulin settlement dynamics, and ICER’s early-phase evidence shift.
Spotify AppleExamining evolving HTA methodologies across Asia-Pacific, RWE integration hurdles in Latin America, gene therapy HEOR strategies in Asia, and digital therapeutics' real-world utility.
Spotify AppleExamining FDA's real-world evidence guidance for accelerated approvals, CMS's Medicare Advantage Star Rating updates, NICE's threshold consultation for specialized tech, and EMA's adaptive licensing initiative for rare diseases.
Spotify AppleHCA's profit warning signals US healthcare access stress; subQ Leqembi approval raises HEOR questions; FTC settlement reshapes insulin pricing dynamics; ICER expands scientific advice for novel therapies.
Spotify AppleExamining the FDA's new RWD guidance, CMS Star Ratings changes, NICE threshold consultation, and EMA's adaptive licensing initiative. A look at the implications for evidence generation and market access.
Spotify AppleExamining US healthcare access pressures, novel Alzheimer's treatment implications, insulin pricing precedent, and early-stage HTA alignment.
Spotify AppleExamining operational hurdles in CMS Part D redesign, ICER's approach to ultra-orphan therapies, FDA decentralized trials guidance, and NICE's RWE integration.
Spotify AppleExamining FDA's accelerated approvals in neurodegeneration, CMS's oncology payment models, NICE's RWE framework evolution, and emerging HTA methodologies in Asia-Pacific.
Spotify AppleProfit warnings signal US access challenges, new Alzheimer's formulations reshape HEOR strategies, insulin pricing settlements reveal systemic flaws, and ICER expands evidence frameworks.
Spotify AppleAnalyzing HCA's profit warning signaling US healthcare access pressures, SubQ Leqembi's approval impact on HEOR strategies, FTC insulin pricing settlement implications, and ICER's expanded scientific advice program.
Spotify AppleExamining evolving regulatory frameworks for real-world evidence, Medicare payment system changes, digital health HTA integration, and emerging sustainability metrics in value assessments.
Spotify AppleHCA profit warning signals US healthcare access challenges; subQ Leqembi approval transforms Alzheimer's HEOR landscape; FTC insulin settlement reshapes PBM practices; ICER expands scientific advice services.
Spotify AppleExamining digital health HTA hurdles, emerging market pricing dynamics, blockchain for RWE, and sustainability metrics in value frameworks.
Spotify AppleHCA's profit warning signals US healthcare access pressures; subcutaneous Leqembi, FTC insulin settlement, and ICER expansion reshape value strategies.
Spotify AppleExamining CMS Part D gene therapy coverage, FDA RWE guidance, NICE digital health HTA, and EU Critical Medicines Act impact on HTA timelines.
Spotify AppleUS hospital chain HCA's profit warning signals systemic access challenges; subQ Leqembi approval reshapes Alzheimer's HEOR; FTC insulin settlement impacts PBMs; ICER expands scientific advice scope.
Spotify AppleHCA's profit warning signals US hospital system strain; subcutaneous Leqembi approval reshapes Alzheimer's evidence strategy; FTC insulin settlement impacts pharmacy benefit managers; ICER expands scientific advice capacity.
Spotify AppleHCA profit warning signals US healthcare access pressures; subQ Leqembi approval changes Alzheimer's HEOR; FTC insulin settlement sets pricing precedent; ICER expands scientific advice.
Spotify AppleThis episode explores the CMS shift in Medicare Advantage Star Ratings, FDA guidance on decentralized trials, ICER's new framework for gene therapies, and NICE's updated RWE guidance.
Audio unavailable here — listen on Spotify
Spotify AppleExamining CMS's Medicare Advantage rating reforms, FDA's decentralized trial guidance, ICER's gene therapy framework, and NICE's RWE expansion. Key shifts in evidence generation and value assessment.
Audio unavailable here — listen on Spotify
Spotify AppleHCA's profit warning signals hospital financial stress; subQ Leqembi raises administration cost questions; FTC insulin settlement pressures PBMs; ICER's expanded advice reshapes evidence timelines.
Audio unavailable here — listen on Spotify
Spotify AppleExamining evolving HTA methodologies for complex therapies, IRA's influence on RWE strategies, patient-centric outcomes in rare diseases, and digital health integration challenges.
Spotify AppleAnalyzing systemic healthcare stressors, novel formulation evidence requirements, insulin pricing precedents, and evolving evidence assessment frameworks.
Spotify AppleExamining US healthcare system pressures, novel formulation approvals, PBM transparency, and evolving evidence generation strategies.
Spotify AppleExamining HCA's profit warning signals, subcutaneous Leqembi's HEOR path, FTC insulin pricing impact, and ICER's expanded scientific advice.
Spotify AppleExamining CMS Part D implementation challenges, ICER's novel Alzheimer's endpoints, EMA's adaptive pathway expansion, and FDA's gene therapy breakthrough updates.
Spotify AppleHCA's uninsured surge signals systemic access challenges; subQ Leqembi reshapes Alzheimer's evidence needs; FTC insulin settlement alters PBM dynamics; ICER's Evidence First program redefines early engagement.
Spotify AppleExamining US healthcare access pressures, new Alzheimer's treatment formulations, insulin pricing enforcement, and evolving evidence strategies.
Spotify AppleExamining HCA's profit warning impact on US healthcare access, SubQ Leqembi approval HEOR implications, FTC insulin pricing settlement, and ICER scientific advice expansion.
Spotify AppleExamining HCA's profit warning signaling U.S. healthcare access pressures, subcutaneous Leqembi's HEOR implications, FTC's insulin pricing settlement, and ICER's expanded scientific advice program.
Spotify AppleHospital profit warnings and regulatory settlements signal systemic US healthcare access challenges, while new drug approvals and evidence frameworks evolve rapidly.
Spotify AppleExamining US healthcare system pressures, novel drug evidence challenges, insulin pricing enforcement, and Medicaid policy shifts shaping market access strategies.
Spotify AppleEMA launches pediatric RWE pilot for rare diseases; ISPOR 2026 highlights PRO framework shifts; CMS proposes Medicaid rebate changes; HTAI-IQVIA launches global RWE database.
Listen Spotify AppleHospital system financial pressures, insulin pricing settlements, new Alzheimer's formulation approvals, and evolving HTA evidence strategies.
Listen Spotify AppleExamining RWE adoption challenges, digital therapeutics value assessment, orphan drug evidence standards, and AI's role in HTA methodologies.
Listen Spotify AppleExamining evolving HTA methodologies, CMS coverage shifts, patent settlement impacts, and NICE's equity framework.
Listen Spotify AppleExamining evolving HTA frameworks in Asia-Pacific, Canada's pricing reforms, RWE integration barriers in Latin America, and gene therapy evidence strategies in Asia.
Listen Spotify AppleNavigating EU HTA regulation teething problems, CMS Part D redesign implementation barriers, RWE utility in accelerated approvals, and gene therapy cost-effectiveness thresholds in high-income markets.
Listen Spotify AppleExamining CMS Part D redesign, ICER's Alzheimer's report, EMA's rare disease pathway, and FDA's Breakthrough expansion.
Listen Spotify AppleFDA approves first KRAS inhibitor in NSCLC; EMA recommends SMA gene therapy; NICE proposes £50k QALY threshold; JCA faces 40% request surge.
Listen Spotify AppleHCA's profit warning signals US healthcare access pressures; SubQ Leqembi's approval reshapes Alzheimer's HEOR; FTC insulin pricing settlement impacts formulary dynamics; ICER expands scientific advice amid evidence gaps.
Listen Spotify AppleThis episode examines US pricing pressures on PBMs and discount programs, the growing importance of biomarker-driven therapies in HEOR strategies, and how M&A is accelerating differentiated drug development.
Spotify AppleThis episode examines how US healthcare system strain impacts drug reimbursement, the HEOR implications of administration innovations like subQ Leqembi, and the evolving competitive landscape in oncology and psoriasis treatments.
Spotify AppleExamining emerging challenges in evidence generation and evaluation, from AI in HTA to RWE in emerging markets, as healthcare systems adapt to new realities.
Listen Spotify AppleExamining emerging HTA frameworks in the GCC, Brazil's pricing shifts, Africa's RWE adoption, Australia's digital health challenges, and Japan's gene therapy evidence strategies.
Listen Spotify AppleEU JCA procedural delays, medical device expansion, transatlantic evidence challenges, and ADC portfolio implications.
Listen Spotify AppleExamining divergent HTA approaches across emerging markets, with contrarian views on RWE utility and gene therapy valuation.
Listen Spotify AppleAnalysis of latest JCA reports, CDF recommendations, NICE reversals, and cross-jurisdictional regulatory challenges with HEOR implications.
Listen Spotify AppleAnalysis of emerging JCA reports, CDF recommendations, NICE reversal on MRD endpoints, and transatlantic regulatory divergence with HEOR implications.
Listen Spotify AppleEU JCA reports reveal methodological tensions, ADC CDF recommendations signal HTA gaps, NICE reversals challenge MRD endpoints, and regulatory divergence complicates HEOR strategies.
Listen Spotify AppleExamining evolving HTA methodologies in Asia-Pacific, RWE adoption challenges in emerging markets, digital therapeutics evidence gaps, and orphan drug RWE complexities.
Listen Spotify AppleThis episode covers PRAC valproate conclusions, HTA methodological updates in the Middle East, Canadian pricing policy developments, RWE integration challenges in Latin America, and gene therapy HEOR strategies in Asia.
Listen Spotify AppleAnalysis of recent JCA reports, NICE reversals, and transatlantic regulatory divergences with HEOR implications.
Listen Spotify AppleDeep dive into emerging JCA assessments, ADC portfolio implications, surrogate endpoint reversals, transatlantic regulatory crises, and pharmacovigilance precedents.
Listen Spotify AppleExamining gene therapy cost-effectiveness hurdles, RWE integration in HTA, PRO utility in value assessments, and evolving HTA approaches for digital health technologies.
Listen Spotify AppleExamining emerging market HTA thresholds, orphan drug RWE demands, digital therapeutics evidence gaps, geopolitical HTA challenges, and precision medicine HEOR shifts.
Listen Spotify AppleExamining evolving HTA methodologies in emerging markets, pricing pressures in Canada, RWE adoption hurdles in Latin America, and gene therapy evidence strategies in Asia-Pacific.
Listen Spotify AppleEMA CHMP approves eight treatments including rare disease; MHRA-NICE issues first aligned guidance; EU JCA scales up to 50 assessments with capacity challenges.
Listen Spotify AppleJCA reports reveal HTA evolution, while ADC evidence gaps and regulatory divergence challenge commercial strategies.
Listen Spotify AppleExamining evolving HTA evidence demands, gene therapy value hurdles, and IRA-driven HEOR shifts. Contrarian perspectives on RWE adoption and evidence generation priorities.
Listen Spotify AppleExamining FDA accelerated oncology approvals, EMA adaptive trial updates, NICE's new cell gene therapy framework, and emerging Asia-Pacific HTA collaboration.
Listen Spotify AppleInterim CDF recommendations for ADCs, NICE reversal on MRD endpoints, regulatory crises, JSC submissions, and EMA emergency trials.
Listen Spotify AppleExamining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints.
Listen Spotify AppleExamining PRAC valproate conclusions, EU JCA capacity expansion, EMA emergency trial frameworks, oral semaglutide UK access, and tovorafenib JCA procedural timelines.
Listen Spotify AppleEpisode 34 unpacks the publication of Europe's first completed JCA report for tovorafenib and what it signals for submissions in the pipeline, the MHRA approval of oral semaglutide and the distinct NICE appraisal challenge it creates, AstraZeneca's camizestrant caught between EU approval and US ODAC rejection, and the PRAC's conclusions on paternal valproate exposure. Marcus and Sara disagree on whether the JCA's handling of indirect comparisons is reassuring or a false comfort, and on whether the camizestrant EU approval is strategically premature.
Listen Spotify AppleEpisode 33 covers NICE's interim CDF recommendation for mirvetuximab soravtansine in platinum-resistant ovarian cancer, the D-VRd reversal and what it signals about population-segmented cost-effectiveness modelling, the convergent avacopan regulatory crisis spanning MHRA, NEJM, PRAC and FDA, and the PRAC's valproate paternal exposure conclusion — a precedent-setting decision to maintain precautions despite explicitly inconsistent evidence.
Listen Spotify AppleExamining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints.
Listen Spotify AppleEpisode 32 covers the publication of the tovorafenib JCA report and what its procedural timeline means for submission planning, the operational launch of medical device JCAs in June 2026, the newly opened JSC window, and the camizestrant case — where the EMA and FDA have reached categorically different conclusions from the same dataset, creating one of the most complex active HEOR files in oncology.
Listen Spotify AppleEMA's PRAC concludes valproate neurodevelopmental risk remains uncertain while EU JCA programme scales to 50 assessments in 2026. Emergency clinical trial guidance opens for consultation as oral GLP-1 approvals expand market access complexity.
Listen Spotify AppleThe EU JCA framework expands into medical devices this month while MHRA-NICE alignment delivers its first coordinated guidance. Europe's HTA infrastructure shows sustained momentum across multiple operational tracks.
Listen Spotify AppleThe UK's MHRA-NICE aligned pathway delivers first guidance this month with 27 early adopter companies, while the EU publishes its second JCA report on tovorafenib. These developments signal coordinated evolution in European HEOR infrastructure prioritizing accelerated patient access.
Listen Spotify AppleThe EU published its first joint clinical assessment report for tovorafenib, marking a milestone in HTA coordination. CHMP approval patterns show a pipeline increasingly skewed toward rare diseases and indication extensions over novel molecules.
Listen Spotify AppleThe EU published its first Joint Clinical Assessment report for tovorafenib while EMA approved oral semaglutide for weight management. JCA capacity constraints emerge as demand for scientific advice exceeds available slots.
Listen Spotify AppleCHMP's May approvals reveal a structural shift toward rare disease development while the Critical Medicines Act introduces mandatory supply chain transparency requirements. AI maintains its dominance in HEOR methodology as NICE expands cardiovascular and digital health guidance.
Listen Spotify AppleMedical device Joint Clinical Assessments begin in June 2026 as the EU HTA Regulation expands beyond oncology medicines. FDA approves first-in-class aldosterone synthase inhibitor baxdrostat while ISPOR signals a shift toward evidence judgment over generation.
Listen Spotify AppleNICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets.
Listen Spotify AppleMarcus and Sara examine the CHMP's May session showing 42% orphan designation rates and debate whether oral semaglutide represents genuine innovation or market expansion. They clash over emergency regulatory collaboration priorities and disagree on JCA capacity constraints for specialty medicines.
Listen Spotify AppleNICE approves third DMD treatment givinostat via Innovative Medicines Fund while CHMP's May output signals structural shift toward rare disease therapies. ISPOR 2026 highlights HEOR's expanding role in policy and value frameworks amid accelerating orphan designation trends.
Listen Spotify AppleEuropean Parliament and Council reach provisional agreement on Critical Medicines Act while EMA approves first RNA-based veterinary vaccine. ISPOR's latest trends report signals the shift from data production to evidence judgment as the new evaluation criterion.
Listen Spotify AppleMultiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals optimization of medicines assessments and HTA regulation coo
Listen Spotify AppleCHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report.
Listen Spotify AppleNICE transforms guidance selection with unified prioritisation framework and EQ-5D-5L implementation while EMA shows regulatory momentum with eight May approvals. The episode examines operational impacts on evidence strategy and market access plannin
Listen Spotify AppleEMA's CHMP delivered eight approvals including nerandomilast for pulmonary fibrosis while the Critical Medicines Act reached provisional political agreement. EU HTA capacity building expands with multilingual eLearning modules as joint clinical asses
Listen Spotify AppleMultiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals optimization of medicines assessments and HTA regulation coordination progress.
Listen Spotify AppleCHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report.
Listen Spotify AppleMedical device JCAs begin this month as NICE refines implementation guidance and biosimilar value assessment approaches. The hosts disagree on whether NICE's procedural simplifications strengthen or weaken evidence standards.
Listen Spotify AppleEMA's CHMP approved eight medicines in May with heavy focus on rare diseases and specialty indications. NICE reveals implementation details for threshold increase while JCA capacity constraints intensify with only 17 scientific advice slots available.
Listen Spotify AppleMedical device JCAs launch in June as NICE implements new prioritisation framework. Trump's MFN commitments clash with reality as pharma raises prices on over 350 products.
Listen Spotify AppleThe EU Critical Medicines Act positions EMA as central authority for supply chain assessments across 200+ substances. AI jumps to #1 in ISPOR trends while NICE advice cuts appraisal timelines by three months.
Listen Spotify AppleNICE's first QALY valuation update in over a decade shows cancer medicines becoming more cost-effective while quality-of-life therapies face higher ICERs. Meanwhile, JCA expansion into medical devices and new NICE prioritisation frameworks signal tighter evidence requirements across the board.
Listen Spotify AppleLSE expert challenges the new UK aligned drug approval pathway as industry-favoring while EU reports progress on 2030 clinical trial targets. NICE approves first HER2-targeted therapy for bile duct cancer as regulatory reforms reshape the clinical research landscape.
Listen Spotify AppleThe EU Critical Medicines Act's provisional agreement introduces supply chain resilience metrics into HTA frameworks, while NICE advances systematic technology adoption and new prioritisation criteria. EMA maintains strong approval rates as European HTA bodies expand beyond traditional pharmacoeconomic assessments.
Listen Spotify AppleNICE transforms guidance selection with unified prioritisation framework and EQ-5D-5L implementation while EMA shows regulatory momentum with eight May approvals. The episode examines operational impacts on evidence strategy and market access planning.
Listen Spotify AppleEMA's CHMP delivered eight approvals including nerandomilast for pulmonary fibrosis while the Critical Medicines Act reached provisional political agreement. EU HTA capacity building expands with multilingual eLearning modules as joint clinical assessments scale to 35 oncology reviews despite persistent bottlenecks.
Listen Spotify AppleHTACG publishes crucial data transparency principles distinguishing commercially confidential information for joint clinical assessments. NICE launches unified prioritisation framework with eight principles from public dialogue, while EMA approves challenging orphan medicines and EFPIA raises MFN pricing access concerns.
Listen Spotify AppleThe EU reaches provisional agreement on the Critical Medicines Act while EMA advances key approvals including nerandomilast for pulmonary fibrosis. HTACG clarifies JCA data transparency requirements and NICE expands semaglutide access for cardiovascular risk reduction.
Listen Spotify AppleThe EU Critical Medicines Act reaches political agreement, reshaping how Europe approaches drug supply security and evidence requirements. The MHRA-NICE aligned pathway goes live — Marcus and Sara examine what both mean for evidence strategy teams.
Listen · ~15 min Spotify AppleNICE approves givinostat for Duchenne muscular dystrophy — the third DMD treatment through the system, benefiting around 530 people in England. Evidence suggests it may delay loss of walking ability by around five years versus established care.
Listen · ~12 min Spotify AppleHTA digital expansion and biosimilar strategy developments in the European market access landscape.
Listen Spotify AppleSubscribe on your platform of choice — or come back here.